Corcept Therapeutics (NASDAQ:CORT) Insider Sells 296 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Roberto Vieira sold 296 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $100.82, for a total transaction of $29,842.72. Following the completion of the sale, the insider directly owned 3,946 shares of the company’s stock, valued at $397,835.72. The trade was a 6.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Roberto Wandenkolk Vieira also recently made the following trade(s):

• On Wednesday, September 2nd, Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock. The shares were sold at an average price of $110.76, for a total transaction of $6,460,963.08.

Corcept Therapeutics Stock Performance

Shares of NASDAQ:CORT traded down $4.57 during midday trading on Friday, hitting $110.29. 17,233,207 shares of the company’s stock traded hands, compared to its average volume of 847,143. The firm’s fifty day moving average price is $108.56 and its two-hundred day moving average price is $75.21. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $126.38. The company has a market cap of $11.92 billion, a PE ratio of 262.60 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34. The firm had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm’s quarterly revenue was up 31.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.29 EPS. As a group, equities research analysts anticipate that Corcept Therapeutics Incorporated will post 1.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently made changes to their positions in CORT. Sequoia Financial Advisors LLC purchased a new position in shares of Corcept Therapeutics during the 2nd quarter valued at approximately $645,000. Tidal Investments LLC increased its stake in shares of Corcept Therapeutics by 9.2% in the second quarter. Tidal Investments LLC now owns 24,218 shares of the biotechnology company’s stock worth $2,106,000 after buying an additional 2,039 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Corcept Therapeutics in the second quarter worth $558,000. NewEdge Advisors LLC raised its holdings in Corcept Therapeutics by 17.9% in the second quarter. NewEdge Advisors LLC now owns 11,041 shares of the biotechnology company’s stock valued at $960,000 after acquiring an additional 1,677 shares in the last quarter. Finally, IFP Advisors Inc raised its holdings in Corcept Therapeutics by 568.4% in the second quarter. IFP Advisors Inc now owns 909 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 773 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
• Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
• Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
• Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
• Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.

Analysts Set New Price Targets

CORT has been the subject of a number of analyst reports. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target for the company. in a report on Monday, July 27th. Truist Financial started coverage on shares of Corcept Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $165.00 price target on shares of Corcept Therapeutics in a research note on Friday. Piper Sandler reiterated an “overweight” rating and issued a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Finally, Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $138.17.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.